To design an anticancer drug capable of inhibiting not only the proliferation of the differentiated tumor cells but also reducing the tumorigenic capability of cancer stem cells (CSCs), the new PtIV prodrugs with axial cinnamate ligands were synthesized. We demonstrate their superior antiproliferative activity in monolayer and 3D spheroid antiproliferative activity tests using panel of cancer cell lines. An outstanding activity was found against rhabdomyosarcoma cells, one of the most problematic and poorly treatable pediatric tumors. The results also suggest that the released PtII compound inhibits antiproliferative activity of cancer cells by DNA-damage mediated mechanism; the released cinnamic acid can trigger processes leading to differentiation, making the CSCs more sensitive to killing by the platinum part of the complex. PtIV complex with axial cinnamate ligands is the first PtIV prodrug capable of overcoming CSCs resistance and induce death in both CSCs and bulk cancer.

Czech Academy of Sciences Institute of Biophysics Kralovoposlka 135 CZ 61265 Brno Czech Republic

Zobrazit více v PubMed

P. N. Ramanan, M. N. A. Rao, Ind. J. Exp. Biol. 1987, 25, 42-43;

M. Sova, Mini-Rev. Med. Chem. 2012, 12, 749-767.

D. Hadjipavlou-Litina, E. Pontiki, Methods Mol. Biol. 2015, 1208, 361-377.

L. Liu, W. R. Hudgins, S. Shack, M. Q. Yin, S. Darawsheh, Int. J. Cancer 1995, 62, 345-350;

G. Qi, J. Chen, C. Shi, Y. Wang, S. Mi, W. Shao, X. Yu, Y. Ma, J. Ling, J. Huang, Cell. Physiol. Biochem. 2016, 40, 589-596;

L.-T. Ng, S.-J. Wu, Evidence-based complementary and alternative medicine : eCAM 2009, 2011, 492148.

E. L. Niero, G. M. Machado-Santelli, J. Exp. Clin. Cancer Res. 2013, 32, 31;

J. Zhang, A. Xiao, T. Wang, X. Liang, J. Gao, P. Li, T. Shi, Biomed. Res. 2014, 25, 405-408;

G.-C. Yen, Y.-L. Chen, F.-M. Sun, Y.-L. Chiang, S.-H. Lu, C.-J. Weng, Eur. J. Pharm. Sci. 2011, 44, 281-287.

M. Ravera, E. Gabano, M. J. McGlinchey, D. Osella, Inorg. Chim. Acta 2019, 492, 32-47;

D. Gibson, J. Inorg. Biochem. 2019, 191, 77-84.

J. J. Wilson, S. J. Lippard, Chem. Rev. 2014, 114, 4470-4495;

R. Faggiani, H. E. Howard-Lock, C. J. L. Lock, B. Lippert, B. Rosenberg, Can. J. Chem. 1982, 60, 529-534.

D. Egas-Bejar, W. W. Huh, Adolesc. Health Med. Ther. 2014, 5, 115-125.

V. Soleimani, M. Rudnicki, Cancer Cell 2011, 19, 157-159.

F. Dela Cruz, Front. Oncol. 2013, 3, 168.

M. D. Hall, M. Okabe, D.-W. Shen, X.-J. Liang, M. M. Gottesman, Annu. Rev. Pharmacol. Toxicol. 2008, 48, 495-535.

D. Wang, S. J. Lippard, Nat. Rev. Drug Discovery 2005, 4, 307-320;

V. Brabec, O. Hrabina, J. Kasparkova, Coord. Chem. Rev. 2017, 351, 2-31.

E. Fennema, N. Rivron, J. Rouwkema, C. van Blitterswijk, J. de Boer, Trends Biotechnol. 2013, 31, 108-115;

C. J. Lovitt, T. B. Shelper, V. M. Avery, Biology 2014, 3, 345-367.

D. Antoni, H. Burckel, E. Josset, G. Noel, Int. J. Mol. Sci. 2015, 16, 5517-5527.

A report from the Australia and New Zealand Children's Cancer Study Group: P. A. Carpenter, L. White, G. B. McCowage, V. Nayanar, I. Toogood, P. J. Shaw, L. Lockwood, K. Tiedemann, Cancer 1997, 80, 489-496;

C. A. S. Arndt, J. A. Stoner, D. S. Hawkins, D. A. Rodeberg, A. A. Hayes-Jordan, C. N. Paidas, D. M. Parham, L. A. Teot, M. D. Wharam, J. C. Breneman, S. S. Donaldson, J. R. Anderson, W. H. Meyer, J. Clin. Oncol. 2009, 27, 5182-5188.

K. Laws, K. Suntharalingam, ChemBioChem 2018, 19, 2246-2253.

C. Keller, D. C. Guttridge, FEBS J. 2013, 280, 4323-4334;

P. Kuppusamy, I. Soundharrajan, D. H. Kim, I. Hwang, K. C. Choi, Phytomedicine 2019, 60, 152873.

D. Walter, S. Satheesha, P. Albrecht, B. Bornhauser, V. D'Alessandro, S. M. Oesch, H. Rehrauer, I. Leuschner, E. Koscielniak, C. Gengler, H. Moch, M. Bernasconi, F. Niggli, B. Schäfer, PLoS ONE 2011, 6, e19506;

J. Neradil, R. Veselska, Cancer Sci. 2015, 106, 803-811.

J. Kim, S. Yu, Y. Xu, Mol. Cell. Oncol. 2018, 5, e1074334.

S. Martins-Neves, D. Oliveira, P. M. Wijers-Koster, A. Abrunhosa, C. Ribeiro, J. Bovee, A.-M. Cleton-Jansen, C. Gomes, Cancer Lett. 2016, 370, 286-295.

A. Gagliardi, N. P. Mullin, Z. Ying Tan, D. Colby, A. I. Kousa, F. Halbritter, J. T. Weiss, A. Felker, K. Bezstarosti, R. Favaro, J. Demmers, S. K. Nicolis, S. R. Tomlinson, R. A. Poot, I. Chambers, EMBO J. 2013, 32, 2231-2247.

V. Kashyap, N. C. Rezende, K. B. Scotland, S. M. Shaffer, J. L. Persson, L. J. Gudas, N. P. Mongan, Stem Cells Dev. 2009, 18, 1093-1108.

K. Suntharalingam, W. Lin, T. C. Johnstone, P. M. Bruno, Y.-R. Zheng, M. T. Hemann, S. J. Lippard, J. Am. Chem. Soc. 2014, 136, 14413-14416;

M. Flamme, P. B. Cressey, C. Lu, P. M. Bruno, A. Eskandari, M. T. Hemann, G. Hogarth, K. Suntharalingam, Chem. Eur. J. 2017, 23, 9674-9682.

Platinum(IV) Derivatives of [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells

Gallium(III) Complex with Cloxyquin Ligands Induces Ferroptosis in Cancer Cells and Is a Potent Agent against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells